Drugs / 123I-ATT001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06650605 | Jul 2024 → Mar 2026 | glioblastoma | Theragnostics Ltd | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 123I-ATT001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06650605 ↗ |
| Action | Inhibit | “I-123 Poly Adenosine Diphosphate Ribose Polymerase I Inhibitor (123I-ATT001)” NCT06650605 ↗ |